  Purpose Both temozolomide ( TMZ) and poly ( ADP-ribose) polymerase ( PARP) inhibitors are active in small-cell lung cancer ( SCLC). This phase II , randomized , double-blind study evaluated whether addition of the PARP inhibitor veliparib to TMZ improves 4-month progression-free survival ( PFS). Patients and Methods A total of 104 patients with recurrent SCLC were randomly assigned 1:1 to oral veliparib or placebo 40 mg twice daily , days 1 to 7 , and oral TMZ 150 to 200 mg/m